Venus Remedies share price hit an intraday high of Rs 355 per share, rising 6 per cent on the BSE in Monday's intraday trade ...

The US company has launched dosing in Taiwan for its Phase II trial of LP-300. In the US, some patients saw 51% tumour ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its ...

【导读】这项研究评估了鞘内培美曲塞（IP）对既往接受过治疗的表皮生长因子受体（EGFR）突变晚期非小细胞肺癌（NSCLC）患者脑膜转移瘤（LM）的治疗效果。2024年12月7日，中南大学湘雅医学院附属肿瘤医院张永昌教授团队在期刊《Heliyon》上发 ...

The benchmark BSE Sensex slipped 0.07% to 81,709.12, while the broader NSE Nifty fell 0.12% to 24,677.8 after the RBI reduced ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

Venus Remedies informed the exchanges on December 6 that it has received the marketing authorisation for Pemetrexed 500mg, a ...

Indian equity benchmarks Nifty 50 and Sensex ended their five-day rally on Friday (December 6) as the Reserve Bank of India ...

Pharma company Venus Remedies bagged a Marketing Authorization nod in the Philippines for Pemetrexed 500mg, an agent used in Chemotherapy while treating lung cancer, sending the share price sharply ...

25 August 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in January 2024.

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for advanced NSCLC with EGFR ...